Dr Lionel Hebbard

Senior Research Fellow
Medicine, Westmead Clinical School
Westmead Millennium Institute for Medical Research

C24 - Westmead Hospital
The University of Sydney
NSW 2006 Australia

T: 02 47019089
W: Projects with this supervisor
Related website

Biographical details

Dr Lionel Hebbard is a scientist, employed as a Senior Research Fellow in the Sydney Medical School and the Storr Liver Unit, Westmead Millennium Institute. He completed his PhD in Germany and for his postdoctoral time he worked at the University Hospital Zurich, Switzerland and the Burnham Institute for Medical Research, La Jolla, USA. He returned from the USA in 2008 to continue his research in Australia. His current research focuses on the role of adiponectin and its receptors in cancer, liver injury and fibrosis and metabolism. [More...]

Research interests

Doctor Hebbard is a PhD scientist with a passionate interest in cancer biology, angiogenesis and in tissue responses to injury.


Stem cells; Cell biology; Liver Disease; Liver fibrosis

International links

United States. (Burnham Institute of Medical Research) Professor Barbara Ranscht Professor Robert Oshima.
Belgium. (University Leuven) Professor Tania Roskams.


2014 | 2013 | 2012 | 2011 | 2010 | 2009


  • Jiang, C., Pu, C., Hou, Y., Chen, Z., Alanazy, M., Hebbard, L. (2014), Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. World Journal of gastroenterology. 20(44), 16464-16473. [Abstract]
  • Alzahrani, B., Iseli, T., Hebbard, L. (2014), Non-viral causes of liver cancer: does obesity led inflammation play a role?. Cancer Letters. 345(2), 223-229. [Abstract]
  • Tian, A., Wilson, G., Lie, S., Wu, G., Hu, Z., Hebbard, L., Duan, W., George, J., Qiao, L. (2014), Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells. Cancer Letters. 351(2), 232-241. [Abstract]
  • Thomsen, K., Grønbæk, H., Glavind, E., Hebbard, L., Jessen, N., Clouston, A., George, J., Vilstrup, H. (2014), Experimental non-alcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function. American Journal of Physiology. Gastrointestinal and Liver Physiology. 307(3), G295-G301. [Abstract]
  • Dai, Y., Jiao, H., Teng, G., Wang, W., Zhang, R., Wang, Y., Hebbard, L., George, J., Qiao, L. (2014), Embelin Reduces Colitis-Associated Tumorigenesis through Limiting IL-6/STAT3 Signaling. Molecular Cancer Therapeutics. 13(5), 1206-1216. [Abstract]
  • Thomsen, K., Hebbard, L., Glavind, E., Clouston, A., Vilstrup, H., George, J., Grønbæk, H. (2014), Non-alcoholic steatohepatitis weakens the acute phase response to endotoxin in rats. Liver International. 34(10), 1584-1592. [Abstract]
  • Hebbard, L., Ranscht, B. (2014), Multifaceted roles of adiponectin in cancer. Best Practice & Research: Clinical Endocrinology & Metabolism. 28(1), 59-69. [Abstract]


  • van der Poorten, D., Samer, C., Ramezani-Moghadam, M., Coulter, S., Kacevska, M., Schrijnders, D., Wu, L., McLeod, D., Bugianesi, E., Komuta, M., Roskams, T., Liddle, C., Hebbard, L., George, J. (2013), Hepatic fat loss in advanced nash: Are alterations in serum adiponectin the cause?. Hepatology. 57(6), 2180-2188. [Abstract]
  • Castro, D., Maurer, J., Hebbard, L., Oshima, R. (2013), ROCK1 Inhibition Promotes the Self-Renewal of a Novel Mouse Mammary Cancer Stem Cell. Stem Cells. 31(1), 12-22. [Abstract]
  • Wilson, G., Tian, A., Hebbard, L., Duan, W., George, J., Li, X., Qiao, L. (2013), Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro. Cancer Letters. 341(2), 224-230. [Abstract]
  • Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., Jacob, G. (2013), Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design. 19(29), 5280-5296. [Abstract]


  • Walker, S., George, J., Hebbard, L. (2012), Animal Models of Hepatocellular Carcinoma. In: Molecular Aspects of Hepatocellular Carcinoma. (pp.116-128).United States: Bentham Science Publishers Ltd..
  • Obeid, S., Hebbard, L. (2012), Role of Adiponectin and Its Receptors in Cancer. Cancer Biology & Medicine. 9(4), 213-220.
  • Hebbard, L. (2012), Role of Angiogenesis in the Development and Therapy of Hepatocellular Carcinoma. In: Molecular Aspects of Hepatocellular Carcinoma. (pp.149-161).United States: Bentham Science Publishers Ltd..


  • Hebbard, L., Cecena, G., Golas, J., Sawada, J., Ellies, L., Charbono, A., Williams, R., Jimenez, R., Wankell, M., Arndt, K., Dejoy, S., Rollins, R., Diesl, V., Follettie, M., Chen, L., Rosfjord, E., Cardiff, R., Komatsu, M., Boschelli, F., Oshima, R. (2011), Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene. 30(3), 301-12. [Abstract]
  • Hebbard, L., George, J. (2011), Animal models of nonalcoholic fatty liver disease. Nature Reviews. Gastroenterology & Hepatology. 8(1), 35-44. [Abstract]


  • Hebbard, L., Maurer, J., Amber, M., Lesperance, J., Hassell, J., Oshima, R., Terskikh, A. (2010), MELK is Upregulated and Required in Mammary Tumor Initiating Cells In Vivo. Cancer research. 70(21), 8863-73. [Abstract]
  • Hebbard, L., George, J. (2010), The chicken or the egg: adipocytes and hepatic insulin resistance. Hepatology. 51(3), 1076-1079. [Abstract]
  • van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J., Ho, V., Hebbard, L., Douglas, M., George, J. (2010), Hepatitis C virus induces the cannabinoid receptor 1. PloS One. 5(9), pii: e1284. [Abstract]


  • Denzel, M., Hebbard, L., Shostak, G., Shapiro, L., Cardiff, R., Ranscht, B. (2009), Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clinical Cancer Research. 15(10), 3256-3264. [Abstract]